“Candy wrapper” effect after drug-eluting stent implantation: Déjà vu or stumbling over the same stone again?
Corresponding Author
Dominick J. Angiolillo MD
Interventional Cardiology Unit, San Carlos University Hospital, Madrid, Spain
Interventional Cardiology Unit, San Carlos University Hospital, Planta 2N, Plaza Cristo Rey s/n, 28040 Madrid, SpainSearch for more papers by this authorManel Sabatá MD, PhD
Interventional Cardiology Unit, San Carlos University Hospital, Madrid, Spain
Search for more papers by this authorFernando Alfonso MD, PhD
Interventional Cardiology Unit, San Carlos University Hospital, Madrid, Spain
Search for more papers by this authorCarlos Macaya MD, PhD
Interventional Cardiology Unit, San Carlos University Hospital, Madrid, Spain
Search for more papers by this authorCorresponding Author
Dominick J. Angiolillo MD
Interventional Cardiology Unit, San Carlos University Hospital, Madrid, Spain
Interventional Cardiology Unit, San Carlos University Hospital, Planta 2N, Plaza Cristo Rey s/n, 28040 Madrid, SpainSearch for more papers by this authorManel Sabatá MD, PhD
Interventional Cardiology Unit, San Carlos University Hospital, Madrid, Spain
Search for more papers by this authorFernando Alfonso MD, PhD
Interventional Cardiology Unit, San Carlos University Hospital, Madrid, Spain
Search for more papers by this authorCarlos Macaya MD, PhD
Interventional Cardiology Unit, San Carlos University Hospital, Madrid, Spain
Search for more papers by this authorAbstract
Encouraging results have been obtained with drug-eluting stents (DESs) to prevent restenosis following PCI. However, DESs are not immune from restenosis and we describe a case of “candy wrapper” effect, commonly observed with intracoronary brachytherapy (IBT). In this article, we review the common drawbacks of DES and IBT and their prevention. Catheter Cardiovasc Interv 2004;61:387–391. © 2004 Wiley-Liss, Inc.
REFERENCES
- 1 Mintz GS, Popma JJ, Hong MK, Pichard AD, Kent KM, Satler LF, Leon MB. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol 1996; 78: 18–22.
- 2 Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, Schatz RA, Guarneri EM, Steuterman S, Morris NB, Leon MB, Tripuraneni P. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336: 1697–1703.
- 3 Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, for the Ravel Study Group. A randomised comparison of a sirolimus-eluting stent with a standard stent for cororonary revascularization. N Engl J Med 2002; 346: 1773–1780.
- 4 Albiero R, Adamian M, Kobayashi N, Amato A, Vaghetti M, Di Mario C, Colombo A. Short- and intermediate-term results of P32 radioactive β-emitting stent implantation in patients with coronary artery disease: the Milan dose-response study. Circulation 2000; 101: 18–26.
- 5 Costa M, Sabaté M, van der Giessen WJ, Kay IP, Cervinka P, Ligthart JM, Serrano P, Coen VL, Levendag PC, Serruys PW. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999; 100: 789–792.
- 6 Sabaté M, Costa MA, Kozuma K, Kay IP, van der Giessen WJ, Coen VL, Ligthart JM, Serrano P, Levendag PC, Serruys PW. Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy. Circulation 2000; 101: 2467–2471.
- 7 Waksman R, Ajani AE, White RL, Pinnow E, Dieble R, Bui AB, Taaffe M, Gruberg L, Mintz GS, Satler LF, Pichard AD, Kent KK, Lindsay J. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial Plus 6 Months of Clopidogrel (WRIST PLUS). Circulation 2001; 103: 2332–2335.
- 8 Verin V, Popowski Y, de Bruyne B, Baumgart D, Sauerwein W, Lins M, Kovacs G, Thomas M, Calman F, Disco C, Serruys PW, Wijns W. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. N Engl J Med 2001; 344: 243–249.
- 9 Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau HN, Colombo A, Di Mario C, Guagliumi G, Hauptmann KE, Pitney MR, Lansky AJ, Stertzer SH, Yock PG, Fitzgerald PJ. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to Compare Restenosis Rate Between QueST and QuaDS-QP2 (SCORE). Circulation 2002; 106: 1788–1793.
- 10 Grube E, Silber SM, Eugene K. TAXUS I: prospective, randomized, double-blind comparison of NIRx stents coated with paclitaxel in a polymer carrier in de-novo coronary lesions compared with uncoated controls. Circulation 2001; 104(Suppl 2): II463.
- 11 Ako J, Morino Y, Honda Y, Terashima M, Asan AHM, Jaeger JL, Simonton CA, Holmes DR, Fischell TA, Fitzgerald PJ. Serial stent edge analysis following sirolimus eluting stent implantation: interim IVUS results from the SIRIUS trial. Circulation 2002; 106: II519.
- 12 Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559–564.
- 13 Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents, part 2. Circulation 2003; 107: 2383–2389.
- 14 Sabaté M, Serruys PW, van der Giessen WJ, Ligthart JM, Cohen VL, Kay P, Gizel AL, Wardeh AJ, den Boer A, Levendag PC. Geometric vascular remodelling after balloon angioplasty and beta-radiation therapy: a three-dimensional intravascular ultrasound study. Circulation 1999; 100: 1182–1188.
- 15 Kozuma K, Costa MA, Sabaté M, Serrano P, van Der Giessen WJ, Ligthart JM, Coen VL, Levendag PC, Serruys PW. Late stent malapposition occurring after intracoronary beta-irradiation detected by intravascular ultrasound. J Invas Cardiol 1999; 11: 651–655.
